https://www.selleckchem.com/pr....oducts/4-hydroxynone
Important issues were raised by the users with implications for the development and deployment of GS2. Integrating the technology into existing IT infrastructure may facilitate caregivers' acceptance. Further clinical studies of the performance and potential health outcomes are warranted.OBJECTIVE To assess the long-term outcomes of patients with temporal lobe epilepsy and CSF anti-glutamate decarboxylase antibodies (GAD65-Abs). METHODS We retrospectively analyzed the clinical records of 35 patients with temporal lobe epilepsy
Like
Comment
Share
